Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C26H33NO2 |
| Molecular Weight | 391.5457 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 4 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(C)=C/C(=O)NC2=CC=C(O)C=C2
InChI
InChIKey=AKJHMTWEGVYYSE-FXILSDISSA-N
InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+
| Molecular Formula | C26H33NO2 |
| Molecular Weight | 391.5457 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 4 |
| Optical Activity | NONE |
Fenretinide (4-HPR) is an orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities. Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types. This agent also inhibits tumor growth by modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid receptor-independent apoptotic properties. Phase III clinical trial data has suggested that fenretinide reduces breast cancer relapse in pre-menopausal women. Fenretinide is the most studied retinoid in breast cancer chemoprevention clinical trials due to its selective accumulation in breast tissue and its favorable toxicological profile. This agent showed a significative reduction of the incidence of second breast tumors in premenopausal women confirmed after 15-year followups. Fenretinide, a drug being developed by Sirion Therapeutics, slowed the progression of advanced dry age-related macular degeneration (AMD) by 45 percent for people receiving a higher dose of the treatment in a Phase II clinical trial. Sirion has been granted a Fast Track designation for the treatment by the FDA. Fenretinide is in phase II clinical trials for the treatment of B-cell lymphoma, chronic lymphocytic leukemia. It is also in phase I clinical trials for the treatment of cystic fibrosis.
CNS Activity
Curator's Comment: Animal studies suggest that fenretinide can cross the blood-brain barrier, probably due to its lipophilicity. Clinical trials from patients with glioma indicated that 4-HPR is able to cross the blood brain barrier (BBB), suggesting its potential for the treatment of central nervous system tumors.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 220.0 nM [EC50] | |||
Target ID: CHEMBL2021749 |
2.32 µM [IC50] | ||
Target ID: CHEMBL3100 |
56.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7.3 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/16034523 |
1800 mg/m² 2 times / day multiple, oral dose: 1800 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: [NO STEREO] NSC-LSC-1|[NO STEREO] PACLITAXEL |
FENRETINIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
60.3 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/16034523 |
1800 mg/m² 2 times / day multiple, oral dose: 1800 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: [NO STEREO] NSC-LSC-1|[NO STEREO] PACLITAXEL |
FENRETINIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/16034523 |
1800 mg/m² 2 times / day multiple, oral dose: 1800 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: [NO STEREO] NSC-LSC-1|[NO STEREO] PACLITAXEL |
FENRETINIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Subacute toxicity of all-trans- and 13-cis-isomers of N-ethyl retinamide, N-2-hydroxyethyl retinamide, and N-4-hydroxyphenyl retinamide. | 1983 Sep 15 |
|
| Abnormal retinal function associated with fenretinide, a synthetic retinoid. | 1986 Jan |
|
| Phase II trial of fenretinide [N-(4-hydroxyphenyl) retinamide] in myelodysplasia: possible retinoid-induced disease acceleration. | 1989 |
|
| Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. | 1995 Jan 15 |
|
| Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation. | 1997 Nov |
|
| Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms. | 1999 Nov-Dec |
|
| Effects of body weight gain reduction resulting from chemopreventive agent treatment on mammary gland morphology. | 2002 |
|
| Identification of retinoid-modulated proteins in squamous carcinoma cells using high-throughput immunoblotting. | 2004 Apr 1 |
|
| Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells. | 2004 May |
|
| The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. | 2005 Jun 15 |
|
| Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells. | 2005 Nov |
|
| Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. | 2005 Oct |
|
| N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. | 2005 Oct 15 |
|
| Increased level of the p67phox subunit of NADPH oxidase by 4HPR in head and neck squamous carcinoma cells. | 2005 Sep |
|
| Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression. | 2006 Feb 1 |
|
| The CLN9 protein, a regulator of dihydroceramide synthase. | 2006 Feb 3 |
|
| Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. | 2007 Apr 23 |
|
| Increased expression of the MGMT repair protein mediated by cysteine prodrugs and chemopreventative natural products in human lymphocytes and tumor cell lines. | 2007 Feb |
|
| Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours. | 2007 Mar |
|
| p-Dodecylaminophenol derived from the synthetic retinoid, fenretinide: antitumor efficacy in vitro and in vivo against human prostate cancer and mechanism of action. | 2008 Feb 1 |
|
| Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets. | 2011 Nov 15 |
Sample Use Guides
Individuals participating in the Phase II study received either one of two oral doses of fenretinide — 300 mg or 100 mg. While both doses slowed the growth of the harmful lesions associated with advanced dry AMD (also known as geographic atrophy), the higher dose was more effective.
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: Fenretinide inhibits OVCAR-5 cell proliferation and viability at concentrations higher than 1 uM, with 70-90% growth inhibition at 10 microM. Fenretinide (1 uM) significantly inhibits OVCAR-5 invasion after 3 days preincubation. Endothelial cells treated with 1 uM 4-HPR fails to form tubes, but forms small cellular aggregates. https://www.ncbi.nlm.nih.gov/pubmed/15816545
At the measured IC(50) of 10 uM, 4-HPR led to a 44-68% reduction in [(3)H]thymidine incorporation, a >3-fold increase in de novo ceramide levels, a 2.7-fold increase in ROS, and minor increases in markers of apoptosis in human pancreatic cancer cell lines.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:50:52 GMT 2025
by
admin
on
Mon Mar 31 17:50:52 GMT 2025
|
| Record UNII |
187EJ7QEXL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
409913
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
||
|
FDA ORPHAN DRUG |
236106
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
||
|
FDA ORPHAN DRUG |
615217
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
||
|
FDA ORPHAN DRUG |
74193
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
||
|
FDA ORPHAN DRUG |
209805
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
||
|
NCI_THESAURUS |
C804
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
||
|
FDA ORPHAN DRUG |
303210
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
||
|
FDA ORPHAN DRUG |
621117
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
||
|
FDA ORPHAN DRUG |
404013
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/06/427
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID2032005
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
DB05076
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
CHEMBL7301
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
SUB07595MIG
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
C1098
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
FENRETINIDE
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
5288209
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
U-72
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
65646-68-6
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
D017313
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
5516
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
760419
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
100000081507
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
42588
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
m5295
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | Merck Index | ||
|
187EJ7QEXL
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
